ArticleBMC cancer2025
The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gastric Juice miR-106a-5p as a Non-Invasive Biomarker of Neuroinflammation and Neurodegeneration: A Prospective Observational Study.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to investigate the potential value of circulating miRNAs in the diagnosis of peritoneal carcinomatosis (PC) in patients with gastric cancer (GC). A quantitative reverse-transcription polymerase chain reaction (qRT-PCR) method was optimized for the measurement of plasma miRNAs. The concentrations of 11 plasma miRNA transcripts were analyzed in 13 pairs of GC patients with PC (GC/PC) and without PC (GC/NPC) using qRT-PCR. The plasma levels of miR-9 and miR-106a were further validated in 30 pairs of GC/PC and GC/NPC patients, as well as in 35 healthy controls (HC), followed by receiver operating characteristic (ROC) curve analysis. Serum levels of carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) were also measured. Primary screening and further validation revealed significantly lower plasma miR-9 levels in the GC/PC group than in the GC/NPC and HC groups (p < 0.001). Conversely, plasma miR-106a and serum CA125 levels, but not CEA levels, were significantly higher in the GC/PC group than in the GC/NPC and HC groups (p < 0.001). No significant differences were observed in plasma miR-9 and miR-106a levels between the GC/NPC and HC groups. ROC analyses indicated that plasma miR-9 yielded an area under the curve (AUC) of 0.776 (95% confidence interval [CI] 0.673-0.859, p < 0.001) with 67.4% sensitivity and 93% specificity, and miR-106a had an AUC of 0.830 (95% CI 0.743-0.916, p < 0.001) with 72.1% sensitivity and 83.7% specificity in distinguishing the GC/PC group from the GC/NPC group. Moreover, the diagnostic performances of plasma miR-9 and miR-106a were comparable with that of CA125 (p > 0.05). Kaplan-Meier survival analysis demonstrated that high plasma levels of miR-106a (hazard ratio (HR) = 0.44, 95% CI 0.19-1.00, p = 0.040) and low levels of miR-9 (HR = 0.43, 95% CI 0.18-1.02, p = 0.042) were significantly associated with reduced overall survival in GC/PC patients. Taken together, these findings suggest that plasma miR-9 and miR-106a may serve as promising non-invasive biomarkers for both the diagnosis and prognosis of PC in patients with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.